Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis

20253 citationsJournal Articlegold Open Access

Authors

Kelsey D. Oliva · Goethe University Frankfurt

L Arnold · Regio (Germany)

Lucie Heinzerling · Regio (Germany)

Friedegund Meier · National Center for Tumor Diseases

Sören Hartmann · National Center for Tumor Diseases

Katharina Meier · Humboldt-Universität zu Berlin

Julia Huynh ·

Abstract

In this retrospective analysis, infliximab appeared to be effective and safe for the treatment of steroid-refractory irHepatitis, with no evidence of hepatotoxicity.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Hepatitis B Virus Studies

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 13, Issue 9, pp. e013038-e013038

DOI: 10.1136/jitc-2025-013038

Field-Weighted Citation Impact: 3.29

Command Palette

Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis

Authors

Abstract

Topics & Keywords

Publication Details